Flag of the European Union EU Clinical Trials Register Help

Clinical trials for LABA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    344 result(s) found for: LABA. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-003127-11 Sponsor Protocol Number: CQVA149A3401 Start Date*: 2014-02-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A prospective, multicenter, 12-week, randomized open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms o.d.) or indacaterol maleate and glycopyrronium bromide fixed-d...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) SK (Completed) BE (Completed) EE (Completed) LV (Completed) IE (Completed) SE (Completed) AT (Completed) PT (Completed) IT (Completed) GB (Completed) DK (Completed) GR (Completed) HU (Completed) PL (Completed) ES (Completed) DE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2014-004775-23 Sponsor Protocol Number: MK-0476-383 Start Date*: 2015-04-08
    Sponsor Name:Merck Frosst Canada Ltd.
    Full Title: RADAR: SingulaiR® in Asthma anD Allergic Rhinitis An 8 week multicenter, open-label, observational study to evaluate the effectiveness of adding Montelukast Sodium (SINGULAIR®) 10 mg per day to inh...
    Medical condition: Adult asthma and allergic rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002899-25 Sponsor Protocol Number: CQVM149B2302 Start Date*: 2015-12-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, 52-week, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) DE (Completed) SK (Completed) PT (Completed) AT (Completed) HU (Completed) NL (Completed) FI (Completed) BE (Completed) ES (Completed) DK (Completed) LV (Completed) GR (Completed) FR (Completed) BG (Completed) IE (Completed) HR (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002078-45 Sponsor Protocol Number: FG-506-17-05 Start Date*: 2004-11-01
    Sponsor Name:Fujisawa GmbH
    Full Title: A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TACROLIMUS MDI AS ADD-ON THERAPY TO ICS AND LABA IN MODERATE TO SEVERE PERSISTENT ASTHMATIC PATIENTS
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10003553 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000302-28 Sponsor Protocol Number: EffICIENCY Start Date*: 2020-05-04
    Sponsor Name:Mundipharma Pharmaceuticals S.L.
    Full Title: Open randomized low interventional clinical trial to compare efficiency in symptom control between fluticasone propionate/formoterol k-haler at medium strength versus an high strength ICS/LABA for ...
    Medical condition: Persistent moderate asthma uncontrolled
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020407-73 Sponsor Protocol Number: D9830C00008 Start Date*: 2010-10-27
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind, placebo-controlled, randomised, parallel-group, phase-II, multi-centre study to assess the efficacy, safety and tolerability of 4 twice daily doses and 2 once daily doses of AZD1981...
    Medical condition: asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2022-001805-40 Sponsor Protocol Number: TRICORDA Start Date*: 2023-03-27
    Sponsor Name:Hospital Universitario Lucus Augusti
    Full Title: Increase in inhaled corticosteroid dose vs triple therapy in T2-high asthma patients who remain uncontrolled with medium dose inhaled corticosteroids/long-acting β2 adrenergic combination: a real-l...
    Medical condition: Asthma is an important global health problem that affects people of all ages . Despite effective and safe therapeutic options, up to 75% of patients with asthma remain uncontrolled . It remains to ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020440-35 Sponsor Protocol Number: D589BC00004 Start Date*: 2011-09-16
    Sponsor Name:Imperial College London
    Full Title: GR activity in induced sputum macrophages, and a change in inflammatory biomarkers 2-hours after a single dose of either Symbicort®/Budesonide/Formoterol or placebo in Chronic Obstructive Pulmonary...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002828-37 Sponsor Protocol Number: D2912C00003 Start Date*: 2021-09-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose ranging, Multi centre Study to Assess Efficacy and Safety of Inhaled AZD1402 Administered as a Dry Powder Twice Daily for Fou...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001644-29 Sponsor Protocol Number: SAS115359 Start Date*: 2012-05-04
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma.
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) ES (Completed) LT (Completed) SE (Completed) LV (Completed) HU (Completed) CZ (Completed) BE (Completed) NL (Completed) PL (Completed) IT (Completed) DK (Completed) SK (Completed) FI (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019685-87 Sponsor Protocol Number: RO-2455-404-RD Start Date*: 2011-04-27
    Sponsor Name:Takeda Pharma A/S
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 μg versus placebo
    Medical condition: severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) AT (Completed) DK (Completed) GR (Completed) NL (Completed) HU (Completed) SK (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001540-56 Sponsor Protocol Number: 208657 Start Date*: 2019-08-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and cha...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) ES (Ongoing) NL (Completed) DK (Completed) BE (Completed) DE (Completed) SE (Completed) IE (Completed) IT (Completed) GR (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002163-26 Sponsor Protocol Number: D3250C00018 Start Date*: 2013-11-08
    Sponsor Name:AstraZeneca AB
    Full Title: A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequatley contr...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003351-11 Sponsor Protocol Number: GPRI-19102-TRA Start Date*: 2019-12-19
    Sponsor Name:GPRI
    Full Title: Triple therapy effectiveness in COPD patients with characteristics of asthma: A pragmatic Primary Care trial - The TRACkER trial
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005523-34 Sponsor Protocol Number: NAI002/I Start Date*: 2006-04-11
    Sponsor Name:University of Dundee (Research & Innovation Services)
    Full Title: A PROOF OF CONCEPT STUDY TO EVALAUTE EFFECTS INTRANASAL SALMETEROL AND FLUTICASONE GIVEN ALONE AND IN COMBINATION IN ALLERGIC RHINITIS
    Medical condition: Allergic Rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001954-91 Sponsor Protocol Number: EFC15805 Start Date*: 2020-06-04
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstr...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LV (Completed) NL (Completed) LT (Completed) BG (Completed) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) PT (Completed) PL (Prematurely Ended) ES (Prematurely Ended) GR (Completed) BE (Completed) HU (Prematurely Ended) CZ (Completed) SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-005293-22 Sponsor Protocol Number: D589GC00003 Start Date*: 2014-08-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80...
    Medical condition: Asthma
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-001429-34 Sponsor Protocol Number: TRITEX_COPD Start Date*: 2021-10-05
    Sponsor Name:University Hospital Mutua de Terrassa
    Full Title: Utility of inhaled extrafine triple therapy with glycopyrronium bromide, formoterol fumarate dihydrate and beclometasone dipropionate to improve expiratory flow limitation in severe COPD exacerbati...
    Medical condition: Severe exacerbation of chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003351-11 Sponsor Protocol Number: 20120141 Start Date*: 2013-03-08
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10003561 Asthma, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IE (Prematurely Ended) IT (Completed) GR (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004655-75 Sponsor Protocol Number: D5970C00002 Start Date*: 2017-07-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate fixed-dose combination relative to Umeclidinium/V...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 03:14:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA